Browsing: ESR1m

Diagnosis

107 Updated Results and an Exploratory Analysis of ESR1 Mutations (ESR1m) Circulating Tumor DNA (ctDNA) Dynamics From SERENA-6, a Phase III Trial of Camizestrant + CDK4/6 Inhibitor (CDK4/6i) for Emergent ESR1m During First-Line (1L) Endocrine-Based Therapy and Ahead of Disease Progression in Patients With HR+/HER2– Advanced Breast Cancer (ABC)

By 0

BackgroundAt SERENA-6 interim analysis, switching to camizestrant, with continued CDK4/6 inhibitor (CDK4/6 i), at ESR1 mutationemergence during first-line aromatase inhibitor…